Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 2/20 | 0.33 |
| ▸ | CCNC | P24863 | 3/20 | 0.32 |
| ▸ | CDK8 | P49336 | 3/20 | 0.32 |
| ▸ | ALPL | P05186 | 2/20 | 0.31 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | ALPG | P10696 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20008981 | 0.85 | CPA1 (0.34) | KDM5ACCNCCDK8 | |
| SCHEMBL4453713 | 0.80 | ALDH1A1 (0.41) | KDM5AALPLPLAAALPGALDH1A1 | |
| SCHEMBL20012745 | 0.79 | KDM5A (0.31) | KDM5ACCNCCDK8 | |
| SCHEMBL1507952 | 0.71 | FAAH (0.36) | ALPLPLAAALPGALDH1A1 | |
| SCHEMBL18038750 | 0.69 | — | — | |
| SCHEMBL14857100 | 0.68 | KDM5A (0.32) | KDM5AALPLPLAAALPGALDH1A1 | |
| SCHEMBL14857102 | 0.68 | KDM5A (0.32) | KDM5AALPLPLAAALPGALDH1A1 | |
| SCHEMBL26186634 | 0.68 | CYP2E1 (0.30) | — | |
| SCHEMBL21149908 | 0.67 | — | — | |
| SCHEMBL20306252 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3262036-B1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | KDM5A 1915/4885CCNC 3381/4885CDK8 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.